Menu Search
Equities

PTC Therapeutics Inc

PTCT:NSQ

PTC Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)43.90
  • Today's Change1.01 / 2.35%
  • Shares traded120.41k
  • 1 Year change+103.05%
  • Beta0.6183
Data delayed at least 15 minutes, as of Nov 22 2024 18:38 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy3
Outperform4
Hold6
Sell2
Strong Sell1

Share price forecast in USD

The 14 analysts offering 12 month price targets for PTC Therapeutics, Inc. have a median target of 45.00, with a high estimate of 66.00 and a low estimate of 26.00. The median estimate represents a 4.92% increase from the last price of 42.89.
High53.9%66.00
Med4.9%45.00
Low-39.4%26.00

Earnings history & estimates in USD

On Nov 07, 2024, PTC Therapeutics, Inc. reported 3rd quarter 2024 losses of -1.39 per share. This result was in line with the consensus of the 13 analysts following the company and exceeded last year's 3rd quarter results by 21.02%.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+2.36%
PTC Therapeutics, Inc. reported annual 2023 losses of -8.37 per share on Feb 29, 2024.
Average growth rate-19.92%
More ▼

Revenue history & estimates in USD

PTC Therapeutics, Inc. had 3rd quarter 2024 revenues of 196.79m. This bettered the 172.66m consensus of the 13 analysts covering the company. This was 10.71% below the prior year's 3rd quarter results.
Average growth rate+4.72%
PTC Therapeutics, Inc. had revenues for the full year 2023 of 937.82m. This was 34.20% above the prior year's results.
Average growth rate+32.36%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.